Arcellx shares skyrocketed 80% pre-market after Gilead Sciences agreed to acquire the biotech for $7.8 billion. The deal offers $115 per share in cash plus a CVR, a 68% premium. Gilead, already an 11.5% owner, expects the acquisition to boost earnings by 2028, pending FDA approval of Arcellx's multiple myeloma treatment.